Text

Aligning drug performance and reimbursement

Optum and Merck collaborate on reimbursement model design.

Text

Optum® and Merck have entered a multi-year collaboration to explore value-based and pay-for-performance models, known as Outcomes-Based Risk Sharing Agreements (OBRSAs). The focus is on developing better approaches to reimburse drug makers based on drug performance.

Text

Enhance OBRSAs design and performance

Optum and Merck are using real-world data to co-develop and test advanced predictive models. The companies will also co-design OBRSAs to reduce clinical and financial uncertainty around payment for prescription drugs.

Learn more